drugset / Trial / NCT01240928
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib trial that evaluates the safety and tolerability of MK-2206 given in combination with exemestane +/- goserelin in pre- and post-menopausal patients with hormone receptor-positive metastatic breast cancer.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-2206 | Small molecule | 135 mg | Oral |
| Background | Exemestane | Small molecule | 25 mg | Oral |
| Background | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |